Claims
- 1. A method for the treatment of hepatitis B infection in humans, comprising administering to a patient in need thereof an effective treatment amount of a 2′fluoro-β-D-nucleoside of the formula:
- 2. A method for the treatment of hepatitis C infection in humans, comprising administering to a patient in need thereof an effective treatment amount of the compound of the formula:
- 3. A method for the treatment of abnormal cell proliferation in humans, comprising administering to a patient in need thereof an effective treatment amount of a 2′fluoro-β-L-nucleoside of the formula:
- 4. A 2′-fluoro-(β-D or β-L)-nucleoside of the formula:
- 5. The compound of claim 4, wherein the base is a purine base, R2 is H, monophosphate, diphosphate, triphosphate or acyl, or a pharmaceutically acceptable salt thereof.
- 6. The compound of claim 4, wherein the purine base is selected from the group consisting of guanine, adenine, hypoxanthine, 2,6-diaminopurine and 6-chloropurine, or a pharmaceutically acceptable salt thereof.
- 7. A pharmaceutical composition comprising an effective treatment amount of a 2′-fluoro-(β-D or β-L)-nucleoside of the formula:
- 8. The composition of claim 7, wherein the base is a purine base selected from the group consisting of guanine, adenine, hypoxanthine, 2,6-diaminopurine and 6-chloropurine, or a pharmaceutically acceptable salt thereof.
- 9. A method for the treatment of hepatitis B infection comprising administering to a host in need thereof an effective treatment amount of a 2′-fluoro-(β-D or β-L)-nucleoside of the formula:
- 10. A method for the treatment of hepatitis C infection comprising administering to a host in need thereof an effective treatment amount of a 2′-fluoro-nucleoside of the formula:
- 11. A method for inhibiting the replication of HIV comprising administering to a host in need thereof an effective treatment amount of a 2′-fluoro-(β-D or β-L)-nucleoside of the formula:
- 12. A method for the treatment of abnormal cell proliferation in humans comprising administering to a host in need thereof an effective treatment amount of a 2′-fluoro-nucleoside of the formula:
- 13. A 2′-fluoro-β-L-nucleoside of the formula:
- 14. The compound of claim 13, wherein the base is a purine base, R2 is H, monophosphate, diphosphate, triphosphate or acyl, or a pharmaceutically acceptable salt thereof.
- 15. The comound of claim 14, wherein the purine base is selected from the group consisting of guanine, adenine, hypoxanthine, 2,6-diaminopurine and 6-chloropurine, or a pharmaceutically acceptable salt thereof.
- 16. A pharmaceutical composition comprising an effective treatment amount of a 2′-fluoro-β-L-nucleoside of the formula:
- 17. The composition of claim 16, wherein the base is a pyrimidine base selected from the group consisting of guanine, adenine, hypoxanthine, 2,6-diaminopurine and 6-chloropurine, or a pharmaceutically acceptable salt thereof.
- 18. A method for the treatment of hepatitis B infection comprising administering to a patient in need thereof an effective treatment amount of a 2′-fluoro-β-L-nucleoside of the formula:
- 19. A method for the treatment of hepatitis C infection comprising administering to a host in need thereof an effective treatment amount of a 2′-fluoro-(β-L)-nucleoside of the formula:
- 20. A method for the inhibition of HIV comprising administering to a host in need thereof an effective treatment amount of a 2′-fluoro-β-L-nucleoside of the formula:
- 21. A method for the treatment of abnormal cellular proliferation in humans comprising administering to a host in need thereof an effective treatment amount of a 2′-fluoro-nucleoside of the formula:
- 22. A 2′-fluoro-β-L-nucleoside of the formula:
- 23. The compound of claim 22, wherein the base is a purine base, R2 is H, monophosphate, diphosphate, triphosphate or acyl, or a pharmaceutically acceptable salt thereof.
- 24. The compound of claim 23, wherein the purine base is selected from the group consisting of guanine, adenine, hypoxanthine, 2,6-diaminopurine and 6-chloropurine, or a pharmaceutically acceptable salt thereof.
- 25. A pharmaceutical composition comprising an effective treatment amount of a 2′-fluoro-β-L-nucleoside of the formula:
- 26. The composition of claim 25, wherein the base is a purine base selected from the group consisting of guanine, adenine, hypoxanthine, 2,6-diaminopurine and 6-chloropurine, or a pharmaceutically acceptable salt thereof.
- 27. A method for the treatment of hepatitis B infection comprising administering to a host in need thereof an effective treatment amount of a 2′-β-fluoro-β-L-nucleoside of the formula:
- 28. A method for the treatment of hepatitis C infection comprising administering to a patient in need thereof an effective treatment amount of a 2-fluoro-β-L-nucleoside of the formula:
- 29. A method for the inhibition of HIV comprising administering to a host in need thereof an effective treatment amount of a 2′-fluoro-β-L-nucleoside of the formula:
- 30. A method for the treatment of abnormal cellular proliferation in humans comprising administering to a host in need thereof an effective treatment amount of a 2′-fluoro-β-L-nucleoside of the formula:
- 31. A 2′-fluoro-β-L-nucleoside of the formula:
- 32. The 2′-fluoronucleoside of claim 31, wherein the base is a purine base, R2 is hydrogen, monophosphate, diphosphate, triphosphate or acyl, or a pharmaceutically acceptable salt thereof.
- 33. The 2′-fluoronucleoside of claim 31, wherein the purine base is selected from the group consisting of guanine, adenine, hypoxanthine, 2,6-diaminopurine and 6-chloropurine, or a pharmaceutically acceptable salt thereof.
- 34. A pharmaceutical composition comprising an effective treatment amount of a 2′-fluoro-β-L-nucleoside of the formula:
- 35. The composition of claim 34, wherein the purine base is selected from the group consisting of guanine, adenine, hypoxanthine, 2,6-diaminopurine and 6-chloropurine, or a pharmaceutically acceptable salt thereof.
- 36. A method for the treatment of hepatitis B infection comprising administering to a patient in need thereof an effective treatment amount of a 2′-fluoro-(β-D or β-L)-nucleoside of the formula:
- 37. A method for the treatment of hepatitis C infection comprising administering to a patient in need thereof an effective treatment amount of a 2′-fluoro-nucleoside of the formula:
- 38. A method for inhibiting the replication of HIV comprising administering to a patient in need thereof an effective treatment amount of a 2′-fluoro-β-L-nucleoside of the formula:
- 39. The 2′-fluoro-β-D or β-L-nucleoside of claim 25, wherein R1 and R2 are hydrogen.
- 40. The pharmaceutical composition of claim 16, wherein R1 and R2 of the 2′-fluoro-β-L-nucleoside are hydrogen.
- 41. The method of claim 18, wherein R1 and R2 of the 2′-fluoro-β-L-nucleoside are hydrogen.
- 42. The method of claim 20, wherein R1 and R2 of the 2′-fluoro-β-L-nucleoside are hydrogen.
- 43. The method of claim 21, wherein X of the 2′-fluoro-nucleoside is S.
- 44. The 2′-fluoro-β-L-nucleoside of claim 22, wherein R1 and R2 are hydrogen.
- 45. The pharmaceutical composition of claim 25, wherein R1 and R2 of the 2′-fluoro-β-L-nucleoside are hydrogen.
- 46. The method of claim 27, wherein R1 and R2 of the 2′-fluoro-β-L-arabinonucleoside are hydrogen.
- 47. The method of claim 29, wherein R1 and R2 of the 2′-fluoro-β-L-arabinonucleoside are hydrogen.
- 48. The method of claim 30, wherein X of the 2′-fluoro-β-L-arabinonucleoside is CH2.
- 49. The 2′-fluoro-β-D or β-L-nucleoside of claim 13, wherein R1 is OH or OR3.
- 50. The pharmaceutical composition of claim 16, wherein R1 of the 2′-fluoro-β-L-nucleoside is OH or OR3.
- 51. The method of claim 18, wherein R1 of the 2′-fluoro-β-L-nucleoside is OH or OR3.
- 52. The method of claim 20, wherein R1 of the 2′-fluoro-β-L-nucleoside is OH or OR3.
- 53. The 2′-fluoro-β-L-nucleoside of claim 22, wherein R1 is OH or OR3.
- 54. The pharmaceutical composition of claim 25, wherein R1 of the 2′-fluoro-β-L-nucleoside is OH or OR3.
- 55. The method of claim 27, wherein R1 of the 2′-fluoro-β-L-arabinonucleoside is OH or OR3.
- 56. The method of claim 27, wherein R1 of the 2′-fluoro-β-L-arabinonucleoside is OH or OR3.
Parent Case Info
[0001] This application claims priority to U.S. provisional patent application Nos. 60/075,893, filed on Feb. 25, 1998 and 60/080,569, filed on Apr. 3, 1998.
Government Interests
[0002] The invention described herein was made with Government support under grant number AI3235 1 awarded by the National Institutes of Health. The United States Government has certain rights to this invention.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60075893 |
Feb 1998 |
US |
|
60080569 |
Apr 1998 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09257130 |
Feb 1999 |
US |
Child |
10061128 |
Jan 2002 |
US |